Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung disease

Roivant Sciences reported that its inhaled candidate mosliciguat has successfully completed a Phase 2 trial in patients with interstitial lung disease. The study met its primary endpoint, showing a meaningful change in the measured outcome.

The trial results exceeded the benchmarks typically used by Wall Street analysts to gauge success in mid‑stage studies. This positive readout suggests the drug may move forward toward later‑stage development.

The company highlighted that the inhaled formulation could address an unmet need in a disease area with limited treatment options. Roivant acquired the candidate from Bayer as part of its broader portfolio strategy.